New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
09:11 EDTRTRX, ANGI, AVP, HOT, DRRX, OWW, ITRI, WFM, MDLZ, CRME, LF, URS, SKX, MDCO, CHTR, CMCSA, CSCO, TWCOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Skechers (SKX), up 14%... Orbitz (OWW), up 14%... Retrophin (RTRX), up 29%... ION Geophysical (IO), up 27%... Avon Products (AVP), up 3%. ALSO HIGHER: Time Warner Cable (TWC), up 8.6% after agreeing to be acquired by Comcast (CMCSA) in a $45.2B stock swap deal. Comcast class A shares are down about 2% after the deal announcement. Charter (CHTR), which was also vying to buy TWC, are down 9% after Comcast struck its deal... Cardiome (CRME), up 20% after Brinavess shows positive results in cardiological study. DOWN AFTER EARNINGS: Cisco (CSCO), down 3.7%... Mondelez (MDLZ), down 3%... Starwood Hotels (HOT), down 2.3%... URS Corporation (URS), down 15%... Itron (ITRI), down 22%... Angie's List (ANGI), down 19%... LeapFrog (LF), down 10%... Cabelas (CAB), down 9%... Whole Foods (WFM), down 7%... NetApp (NTAP), down 4.5%. ALSO LOWER: DURECT (DRRX), down 29% after the FDA determined it cannot approve the New Drug Application for POSIDUR in its present form... The Medicines Co. (MDCO), down 13% after an FDA panel voted against approval for cangrelor and the company's shares were downgraded at Jefferies and at Credit Suisse.
News For TWC;CMCSA;CHTR;CSCO;MDLZ;HOT;SKX;WFM;AVP;URS;ITRI;ANGI;LF;OWW;RTRX;CRME;DRRX;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
January 14, 2015
05:18 EDTHOTStarwood, NRG Energy announce new solar installation at The Phoenician
Subscribe for More Information
January 13, 2015
16:00 EDTWFMOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
12:02 EDTHOTStarwood, KFK Group sign deal to open new Westin hotel in Dallas
Subscribe for More Information
07:16 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information
05:46 EDTWFMStocks with implied volatility movement; ARCP WFM
Subscribe for More Information
January 12, 2015
17:29 EDTANGIAngie's List announces paid membership surpasses 3M
Angie's List announced that the company has surpassed 3M paid members, ending 2014 with 3,041,651 members subscribed to the national local services marketplace and consumer review site.
15:49 EDTCMCSAGaiam partners with Comcast to launch Gaiam TV Fit & Yoga
Subscribe for More Information
12:05 EDTANGIWeitz Investment reports 6.29% passive stake in Angie's List
Subscribe for More Information
10:40 EDTAVPStocks with call strike movement; AVP DNR
Avon Products (AVP) April 10 call option implied volatility increased 4% to 63, Denbury Resources (DNR) June 8 call option implied volatility increased 3% to 63 according to IVolatility.
10:34 EDTMDLZFood makers slip as Citi highlights headwinds with downgrades in space
Subscribe for More Information
10:24 EDTAVPOptions with increasing implied volatility
Options with increasing implied volatility: TLM GREK ARNA AVP
10:00 EDTCHTROn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTMDLZOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:52 EDTURSURS-AMEC consortium set to lose GBP 9B nuclear clean-up pact, FT says
Nuclear Management Partners, a consortium made up of URS (URS), France's Areva and Britainís AMEC Foster Wheeler (AMFW), is poised to lose its GBP 9B contract to clean up western Europeís largest nuclear waste site, Sellafield, according to Financial Times. Reference Link
08:08 EDTRTRXRetrophin aquires exclusive right to purchase cholic acid from Asklepion
Retrophin and Asklepion Pharmaceuticals, LLC, a privately held rare disease pharmaceutical development company, today announced the signing of a definitive agreement under which Retrophin has acquired the exclusive right to purchase from Asklepion, all worldwide rights, titles, and ownership of cholic acid for the treatment of bile acid synthesis defects, if approved by the U.S. FDA. Under the terms of the agreement, Retrophin will pay Asklepion an upfront payment of $5M and up to $73M in milestones based on approval and net product sales, plus tiered royalties on future net sales of cholic acid. Retrophin has secured a line of credit from current lenders to cover necessary payments. Cholic acid is being considered for approval in a late-stage review by the FDA and is currently approved in Europe for the treatment of inborn errors in primary bile acid synthesis. It restores endogenous bile acid pool levels while inhibiting abnormal bile acid synthesis. The clinical use of cholic acid has been documented in medical literature for several single enzyme bile acid synthesis defects since the mid-1990s.
07:17 EDTRTRXRetrophin management to meet with Deutsche Bank
Subscribe for More Information
06:28 EDTCSCOCisco positioned for better than expected quarter, says Deutsche Bank
Subscribe for More Information
06:16 EDTMDLZMondelez downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
05:55 EDTAVPStocks with implied volatility movement; RSH AVP
Subscribe for More Information
05:52 EDTCHTRCharter initiated with an Outperform at Wells Fargo
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use